Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000935836-25-000170
Filing Date
2025-02-14
Accepted
2025-02-14 13:40:46
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12314
2 exh99agmt.htm EX-99.1 AGREEMENT 4564
  Complete submission text file 0000935836-25-000170.txt   18616
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Subject) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91004 | Film No.: 25626312
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1 LETTERMAN DRIVE BLDG C, SUITE C3-350 SAN FRANCISCO CA 94129
Business Address 1 LETTERMAN DRIVE BLDG C, SUITE C3-350 SAN FRANCISCO CA 94129 4158014660
Logos Global Management LP (Filed by) CIK: 0001792126 (see all company filings)

EIN.: 833997742 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A